Article ISI SCOPUS
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY  (2008)

Buthionine sulfoximine has anti-Trypanosoma cruzi activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox

Faundez, M; Lopez-Munoz, R; Torres, G; Morello A.; Ferreira J.; Kemmerling U.; Orellana M.; Maya, JD

Abstract

L-Buthionine (S,R)-sulfoximine (BSO) at a dose of 220 mg/kg of body weight/day showed an anti-Trypanosoma cruzi effect in infected mice, increasing their survival rate and decreasing the parasitemias and parasite burden in the hearts. Treatment with BSO plus nifurtimox caused an increase in the survival rate in comparison to the rates with treatment with each drug alone. Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Más información

Título según WOS: Buthionine sulfoximine has anti-Trypanosoma cruzi activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox
Título según SCOPUS: Buthionine sulfoximine has anti-Trypanosoma cruzi activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox
Título de la Revista: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volumen: 52
Número: 5
Editorial: AMER SOC MICROBIOLOGY
Fecha de publicación: 2008
Página de inicio: 1837
Página final: 1839
Idioma: English
URL: http://aac.asm.org/cgi/doi/10.1128/AAC.01454-07
DOI:

10.1128/AAC.01454-07
Notas: ISI, SCOPUS